%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T19:19:22Z
2024-03-29T08:57:33-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T08:57:33-07:00
application/pdf
Heather
2001-686.may02
uuid:589234c2-1dd2-11b2-0a00-2d0927bd7700
uuid:589234c4-1dd2-11b2-0a00-900000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
123 0 obj
[127 0 R]
endobj
124 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.19009 Tw 10 0 0 10 54 713.1616 Tm
[(However)39.8 (, a small number of patients indicated that their)]TJ
0.0928 Tw 0 -1.21 TD
[(foot complaints had changed between )17.8 (T)34.9 (ime 0 and )17.8 (T)34.9 (ime 8,)]TJ
0.1786 Tw T*
(and the changes were small in those who did report any)Tj
0.009 Tc 0.36591 Tw T*
[(change. )54.8 (A)-569.9 (m)0.1 (ore precise assessment of responsiveness)]TJ
0 Tc 0.0426 Tw T*
(should be performed in future studies using an intervention)Tj
0.0379 Tw T*
[(with known ef)17.8 (fectiveness in reducing pain and disability of)]TJ
-0.00011 Tc 0.0276 Tw T*
[(foot complaints. )17.8 (The concurrent validity of the FFI-5pt was)]TJ
0 Tc 0.0715 Tw T*
[(satisfactory)64.9 (. )17.8 (The most pronounced score dif)17.8 (ferences on the)]TJ
0.0706 Tw T*
(Disability scale were seen between patients with and those)Tj
0.3537 Tw T*
(without limited mobility and between those with poor)Tj
0.1107 Tw T*
[(versus good physical functioning. )54.9 (As expected, the lar)17.8 (gest)]TJ
0.01871 Tw T*
[(dif)17.8 (ference on the Pain scale was seen between patients with)]TJ
0.02499 Tw T*
(high and those with low bodily pain.)Tj
-0.00011 Tc 0.35539 Tw 1.2 -1.2 Td
(Another self-administered questionnaire was recently)Tj
0.00951 Tc 0.3654 Tw -1.2 -1.2 Td
[(published by Garrow)64.8 (, )]TJ
/TT1 1 Tf
0.0096 Tc [-0.2 (et al)]TJ
/TT0 1 Tf
0.00951 Tc 0.36549 Tw 12.3371 0 Td
(, the Disabling Foot Pain)Tj
-0.00011 Tc 0.13811 Tw -12.337 -1.2 Td
(Questionnaire \(DFPQ\))Tj
0 Tc 0 Tw 6.5 0 0 6.5 146.1792 535.2618 Tm
(20)Tj
0.13811 Tw 10 0 0 10 152.6792 531.9617 Tm
[(. )55 (Although a comparative study is)]TJ
0.2234 Tw -9.8679 -1.2 Td
(needed to rate the relative merits of both questionnaires)Tj
-0.00011 Tc 0.15041 Tw 0 -1.2 TD
(\(DFPQ and FFI-5pt\), the FFI-5pt appears to have several)Tj
0.07829 Tw T*
(advantages. First, the FFI measures the degree of pain and)Tj
0.06059 Tw T*
[(disability)64.8 (, which is important in assessing the ef)17.7 (fectiveness)]TJ
0 Tc 0.1722 Tw T*
[(of interventions aimed at reducing pain and disability)64.9 (. In)]TJ
-0.00011 Tc 0.16141 Tw T*
(contrast, the DFPQ is aimed at measuring the number of)Tj
0.25011 Tw T*
[(problems and time intensity)64.8 (. Further)39.7 (, the FFI has fewer)]TJ
0.0397 Tw T*
(items \(15 versus 19\) and consists of 2 well defined compo-)Tj
0 Tc 0.1281 Tw T*
(nents \(Pain and Disability; explained variance 65%\), both)Tj
0.19501 Tw T*
[(with high internal consistency)64.9 (. )17.7 (The DFPQ has 4 compo-)]TJ
0.0403 Tw T*
[(nents, with less explained variance \(57%\). Finally)65 (, the FFI-)]TJ
0.0186 Tw T*
(5pt test-retest reliability is good, while that characteristic of)Tj
-0.00011 Tc 0.02499 Tw T*
(the DFPQ is not yet known.)Tj
0.0006 Tc 0.3744 Tw 1.2 -1.2 Td
(The 15 item FFI-5pt is a suitable questionnaire to)Tj
0 Tc -0.03329 Tw -1.2 -1.2 Td
[(measure the ef)17.8 (fect of foot complaints on foot function. It can)]TJ
-0.00861 Tw T*
(be used in both population and intervention studies aimed at)Tj
0.3434 Tw T*
[(reducing pain and disability caused by foot morbidity)65 (.)]TJ
-0.03371 Tw T*
(Further studies in populations with a relatively higher preva-)Tj
-0.00011 Tc 0.20239 Tw T*
(lence of serious illness and relating to responsiveness to)Tj
0 Tc 0.02499 Tw T*
(change are recommended.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
0 Tc 0.0383 Tw 8 0 0 8 54 257.9616 Tm
[(The authors thank the participating general practitioners in )54.9 (Apeldoorn, the)]TJ
-0.0183 Tw 0 -1.25 TD
(physiotherapists Dave van Dijk and Gertie Paalman, and the Department of\
)Tj
-0.00011 Tc 0.0141 Tw T*
[(Physiotherapy of the Gelre Hospital, )54.9 (Apeldoorn, )17.8 (The Netherlands. )17.8 (W)79.7 (e)-0.1 ( also)]TJ
0 Tc 0.06889 Tw T*
(thank the patients for participating in this study and completing the qu\
es-)Tj
0 Tw T*
(tionnaires.)Tj
/TT2 1 Tf
-0.00011 Tc 10 0 0 10 54 193.9617 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 61 183.9617 Tm
[(1.)-875 (Cunningham LS, Kelsey JL. Epidemiology of musculoskeletal)]TJ
1.675 -1.25 Td
[(impairments and associated disability)64.9 (. )54.8 (Am J Public Health)]TJ
0 Tw T*
(1983;74:574-9.)Tj
0.02499 Tw 31.325 68.821 Td
[(2.)-875 (van Saase JLCM, van Romunde LKJ, Cats )54.9 (A, van )17.8 (V)111.1 (andenbroucke)]TJ
1.675 -1.25 Td
[(JP)110.8 (, van )17.7 (V)111.1 (alkenbur)17.8 (g HA. Epidemiology of osteoarthritis: Zoetermeer)]TJ
T*
[(survey)64.9 (. )54.9 (Ann Rheum Dis 1989;48:271-80.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Gorter KJ, Kuyvenhoven MM, de Melker RA. Nontraumatic foot)]TJ
0 Tc 1.675 -1.25 Td
(complaints in older people: a population-based survey of risk)Tj
T*
[(factors, mobility and well-being. J )54.8 (Am Podiatr Med )54.8 (Assoc)]TJ
0 Tw T*
(2000;90:397-402.)Tj
0.0249 Tw -1.675 -1.25 Td
[(4.)-875 (van )17.7 (W)59.8 (yngarden )17.7 (TM. )17.7 (The painful foot. Part I: Common forefoot)]TJ
1.675 -1.25 Td
[(deformities. )54.9 (Am Fam Physician 1997;55:1866-75.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Gorter KJ. Common foot problems [dissertation]. Utrecht:)]TJ
0 Tc 1.675 -1.25 Td
(Universiteit Utrecht; 2001.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (T)34.8 (inetti ME, Speechley M, Ginter SF)79.7 (. Risk factors for falls among)]TJ
0 Tc 1.675 -1.25 Td
[(elderly persons living in the community)64.9 (. N Engl J Med)]TJ
0 Tw T*
(1988;319:1701-7.)Tj
0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (V)111.1 (erbrugge LM, Patrick DL. Seven chronic conditions: their impact)]TJ
1.675 -1.25 Td
[(on US adults\222)-201 (activity levels and use of medical services. )54.8 (Am)]TJ
0.275 -1.25 Td
(J Public Health 1995;85:173-82.)Tj
-1.95 -1.25 Td
[(8.)-875 (Budiman-Mak E, Conrad KJ, Roach KE. )17.8 (The Foot Function Index:)]TJ
1.675 -1.25 Td
[(a measure of foot pain and disability)64.9 (. J Clin Epidemiol)]TJ
0 Tw T*
(1991;44:561-70.)Tj
0.0249 Tw -1.675 -1.25 Td
[(9.)-875 (Saag KG, Saltzman CL, Brown K, Budiman-Mak E. )17.7 (The Foot)]TJ
1.675 -1.25 Td
(Function Index for measuring rheumatoid arthritis pain: evaluating)Tj
T*
[(side-to-side reliability)64.9 (. Foot )54.8 (Ankle 1996;17:506-10.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Domsic R)59.7 (T)73.9 (, Saltzman CL. )54.8 (Ankle Osteoarthritis Scale. Foot )54.8 (Ankle)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1998;19:466-71.)Tj
0.02499 Tw -2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Hutchinson )54.9 (A, McColl E, Cristie M, Riccalton C. Health outcome)]TJ
2.1381 -1.25 Td
[(measures in primary and outpatient care. )54.8 (Amsterdam: Harwood)]TJ
T*
(Academic; 1996.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Jaeschke R, Singer J, Guyatt GH. )54.8 (A)-219.9 (comparison of seven-point and)]TJ
0 Tc 2.175 -1.25 Td
(visual analogue scales. Data from a randomized trial. Control Clin)Tj
T*
[(T)34.9 (rials 1990;1)36.9 (1:43-51.)]TJ
-2.175 -1.25 Td
[(13.)-875 (DeLoach LJ, Higgins MS, Caplan )54.8 (AB, Stif)17.8 (f JL. )17.7 (The visual analog)]TJ
2.175 -1.25 Td
(scale in the immediate postoperative period: intrasubject variability)Tj
T*
[(and correlation with a numeric scale. )54.9 (Anesth )54.9 (Analg 1998;86:102-6.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Briggs M, Closs JS. )54.8 (A)-219.8 (descriptive study of the use of visual)]TJ
2.175 -1.25 Td
(analogue scales and scales for the assessment of postoperative pain)Tj
T*
(in orthopedic patients. J Pain Symptom Manage 1999;18:438-46.)Tj
-2.175 -1.25 Td
[(15.)-875 (McWhinney JR. Disability assessment in population surveys:)]TJ
2.175 -1.25 Td
[(results of the OECD Common Development Ef)17.8 (fort. Rev Epidemiol)]TJ
T*
(Sante 1981;29:413-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Brazier JE, Harper R, Jones NM, et al. )17.7 (V)111 (alidating the SF-36 Health)]TJ
2.175 -1.25 Td
(Survey Questionnaire: new outcome measure for primary care.)Tj
0 Tc T*
(BMJ 1992;305:160-4.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (Aaronson NK, Muller M, Cohen PD, et al. )17.7 (T)34.8 (ranslation, validation,)]TJ
0 Tc 2.175 -1.25 Td
(and norming of the Dutch language version of the SF-36 Health)Tj
T*
(Survey in community and chronic disease populations. J Clin)Tj
T*
(Epidemiol 1998;51:1055-68.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Medical Outcomes )17.7 (T)34.8 (rust. How to score the SF-36 Health Survey)64.8 (.)]TJ
0 Tc 2.175 -1.25 Td
(Boston: New England Medical Center; 1994.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Conrad KJ, Budiman-Mak E, Roach KE, Hedeker D. Impacts of)]TJ
0 Tc 2.175 -1.25 Td
(foot orthoses on pain and disability in rheumatoid arthritics. J Clin)Tj
T*
(Epidemiol 1996;49:1-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Garrow )54.8 (AP)110.7 (, Papageor)17.7 (giou )54.8 (AC, Silman )54.8 (AJ, )17.7 (Thomas E, Jayson MI,)]TJ
0 Tc 2.175 -1.25 Td
(MacFarlane GJ. Development and validation of a questionnaire to)Tj
T*
(assess disabling foot pain. Pain 2000;85:106-13.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:5)Tj
0 Tw -46.2952 -0.0313 Td
(1028)Tj
ET
0 0 0 0 scn
/GS0 gs
102.38 59.08 407.5 -10.83 re
f*
0.5 w
102.38 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
88 0 obj
<>
endobj
106 0 obj
<>
endobj
53 0 obj
<>
endobj
49 0 obj
<>
endobj
22 0 obj
<>
endobj
25 0 obj
<>
endobj
26 0 obj
<>stream
HdVpTs͋ ,1$^Z$@.<+a@#dtFQVVC
Ũ0SUH-kZASQS;w7?n c%[⭛~ǀҿPoV-5r'PoԻuwCbhscaߧΕdoF6/sl{33nYRų|@_n/o͌)|%[y٘
a
۱aR~
X(SV.LC)֨, D &^>,rezw_sߣqb~-=(Db7NNi9QLF?õ\h'ǤýaWkc}2A:O¤\ aw{~.Gmb-i#6<^$DH{}EՌ+lcx1T壄mW3GA)Y-rtH|jVwm8ppY/aie[eӮ~b.XCm9$O
TdTIiQZv.kdI+Veưi1(f2g]ͬ:̊~?bJK' #
Fb^5T$+RJu3M&UV^方H2*MUf3n绱
8؍CS|38>O$B\ήʕIJfO:FT'AV&_' /IKN vm;f^um11f||ʳ&Yuփg$ѕvMwwO#cf0v~?6fS8G/=#'.>cX/seI:Z!WK#HgUn;Hy&;9Yq U#}(1ǼL/NJ= RH_xi8bfNsŷUhM>u:62+}Cؕj?'G4e_{ߪfu^ o/drTG[*c3gA~+&ƾͻ5xsNRj|庽vͭ7sS߹^t"/4ܿ@heaK
dH\xAYii(AqԮQ1eO{;NA| )<_<5!j6@3ӔL y%bIݜ"vk=~&;Ge͝X،`1ihqQ'ώDv;3gh@6XzFvعpLusk;XHǏ5
vÚ}!\Lj:*}\4fGap訢xcg%KfzrӻZiVqdUm2/dvTKbN;Xs̭ٛʋH5{{`~ߊe5zH;)AV=Wў{NlZ4j|jY.r2:s~ʷ(w~ 6|I<%I+<7B)Y1Nlx+В~zPdU#yYc5Fp/YQ:x^X6Ly5GQ/W3-\l4x16'\˸<˭
!vyF
xy16DL}umc42e,Zb^DU*sIG0pO/ihKv. hڜr
B\鼬oakf`
qٍJZi>iuڴlpR\C5pyZʙTL-˛-w|KkZi%^S/L\E[{3ƘhM@L+en8m{}<`+o tbQ>UDqD'eӴUf빥 zFux
tzνYKޝ09ūi=MҶUvJ9ݘ1]]O;p>>(.wwq܁牼eI@V/9b((E
1%*Աm1c4n!fLF5i:5qNې6/B.SG<